Exact Sciences (EXAS) a One Trick Pony But Can Still Turn Heads
Tweet
Share
E-mailGet Alerts EXAS Hot Sheet
Up)Join SI Premium – FREE
Shares of Exact Sciences (Nasdaq: EXAS) moved higher today after the company was featured in a weekend report by Barron’s. The company is developing a test that can detect colon cancers with more accuracy than screenings that are currently in use. If the test is eventually approved by the FDA, Exact Sciences could be acquired for upward of $20 per share, Barron's said.
Shares of Exact Sciences last traded at $11.92, up 2.5 percent from Friday's close.
Shares of Exact Sciences last traded at $11.92, up 2.5 percent from Friday's close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exact Sciences (EXAS) PT Raised to $84 at Baird
- Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
Create E-mail Alert Related Categories
Insiders' BlogRelated Entities
Barron'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
